Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration

A technology for preparing cycloastragenol and drugs, which is applied in the application field of cycloastragenol in the preparation of drugs for protecting the liver and promoting liver damage repair, can solve problems such as the inability to clarify the material basis of the pharmacological activity of astragalus for protecting the liver, and achieve the goal of promoting liver function. Cell proliferation, good protection and therapeutic effect, effect of inhibiting expression

Active Publication Date: 2016-02-24
TAIZHOU DANDING BIOTECH CO LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, astragalus injection or astragaloside IV injection, which is used most clinically, is mainly used to treat cardiovascular and cerebrovascular diseases. There is no new liver-protecting drug made from single-flavored astragalus in the market. Astragalus is widely used in my country. It has been used for many years and has the effect of protecting the liver, but the current research cannot clarify the material basis of the main pharmacological activity of Astragalus as a liver-protecting drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration
  • Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration
  • Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Proliferation-promoting effect of cycloastragenol on normal liver cells

[0026] Rat hepatic cell line BRL-3A cells and human hepatic cell line LO2 cells were spread in 96-well plate at 3×103 per well, with 3 multiple wells in each group. After the cells adhered to the wall, cycloastragenol was added to the final concentrations of 5, 10, 20 μM, the same amount of DMSO was used as the control group, after 72 hours, CCK8 was added, incubated for 1 hour, detected by a microplate reader at 450 nm, and the proliferation efficiency of the cells was calculated by the OD value.

[0027]Experiments have found that cycloastragenol can promote the proliferation of normal liver cells, and its effect is dose-dependent within a certain concentration range.

Embodiment 2

[0028] Example 2: Cycloastragenol inhibits the expression of hepatocyte apoptosis-related proteins

[0029] The human hepatic cell line LO2 cells were spread in 6-well plates at 5×105 per well, at 37°C, 5% CO 2 Cultivate overnight under these conditions, add cycloastragenol in groups to final concentrations of 5, 10, and 20 μM, respectively, and the same amount of DMSO was used as the control group. After 24 hours, the total protein was extracted from the cells, and Western-blot was used to detect the effect of cycloastragenol on the expression of related apoptotic proteins. influences.

[0030] Experimental results such as figure 2 As shown, cycloastragenol has obvious inhibitory effect on the content of phosphorylated P53 protein and Caspase family 3 and 9 protein active molecules, and it is concentration-dependent within a certain range, indicating that cycloastragenol can inhibit apoptosis of normal liver cells role.

Embodiment 3

[0031] Example 3: Protective effect of cycloastragenol on chemical acute liver injury

[0032] Forty C57 male mice were randomly divided into 4 groups, namely blank control group, CCL4 acute liver injury model group, cycloastragenol (CAG) low dose (50 mg / Kg) group and high dose (100 mg / Kg) group. The experiment process was as follows: CAG low-dose and high-dose groups were given intragastric administration for 12 consecutive days, and the blank group and model group were given the same volume of normal saline. After 3 hours of administration on the 12th day, all groups except the blank group were intraperitoneally injected with 10% CCL4 oil solvent (0.1ml / 10g), fasted and had free access to water. After 24 hours, blood was collected, serum was separated, and ALT and AST were determined. Then the mouse was sacrificed by devertebrate, the abdominal cavity was opened, the liver was taken out, weighed, and 0.5 g liver was added with 9 times ice saline, and the tissue was homogeni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of cycloastragenol in preparation of liver-protecting drugs or liver-caring drugs or liver injury treating drugs. Animal and cell experiments indicate that cycloastragenol has the effects of protecting liver, caring liver, and promoting liver injury restoration, thereby having strong application prospects.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a new medical application of cycloastragenol, a triterpenoid saponin compound. Cycloastragenol has a strong activity of promoting liver cell proliferation, inhibits the expression of apoptosis-related proteins, and reduces serum Or ALT, AST, MDA activity and raising SOD activity (p<0.05) in the tissue have better protective and therapeutic effects on chemical liver damage, so it can be used for the preparation of drugs for protecting the liver and treating chemical liver damage . Background technique [0002] Astragaloside IV is the main saponin component of Astragalus. Modern pharmacological studies have proved that Astragalus and its saponins have significant immune regulation, anti-inflammatory, anti-oxidation, anti-ischemic brain damage, and anti-aging. 作用(Clement-KruzelS,etal.Immunemodulationofmacrophagepro-inflammatoryresponsebygoldensealandAstragalusextracts.JMedFood20...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P1/16
CPCA61K9/0019A61K9/08A61K9/2059A61K31/58A61K47/26
Inventor 顾正兵
Owner TAIZHOU DANDING BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap